The Association Between Obesity-Related Indicators and Adverse Outcomes in Ischemic Stroke Patients
NCT ID: NCT06165107
Last Updated: 2025-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
18374 participants
OBSERVATIONAL
2000-09-01
2022-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epicardial Adipose Tissue Volume and Attenuation in Acute Ischemic Stroke
NCT05631808
Obesity Effect on Stroke and Cardiovascular Events
NCT04062643
The Relationship Between Morbid Obesity and Carotid Artery Stenosis
NCT03306771
Effect of Weight Loss and Exercise on Liver and Muscle Fat in Obese Elderly
NCT00779207
Vascular Inflammation Stratified by Body Size Phenotype
NCT01979068
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The variables gathered included the primary test parameters of patients within 24 hours of admission, encompassing age, gender, smoking and alcohol consumption status, arterial blood pressure, fat-related indicators, comorbidities, and the primary treatments administered within the initial 24 hours.
A national multicentre prospective cohort was utilized as the validation cohort for the previous prospective study, wherein comprehensive details regarding inclusion/exclusion criteria and study implementation have been previously documented (Annals of Neurology 2011, 70(2):265-273; Lipids in Health and Disease 2024, 23(1)). The primary institutions involved in this project include: five tertiary cardiovascular institutions in China: Fuwai Hospital, Chinese Academy of Medical Sciences \& Peking Union Medical College (Beijing); The First Affiliated Hospital of Xi'an Jiaotong University (Xi'an); Tongji Hospital, Huazhong University of Science and Technology (Wuhan); Tianjin Cardiovascular Institute (Tianjin); and Daping Hospital, Army Medical University (Chongqing). Data were collected from participants in a prospective cohort study carried out from November 2000 to November 2001 at five research centers in Wuhan, Xi'an, Beijing, Tianjin, and Chongqing in China.
This prospective cohort comprised 1268 patients experiencing their first-ever stroke, with a median follow-up duration of 5 years (range, 4-5.5 years). Individuals with concurrent chronic kidney disease or chronic respiratory ailments were excluded from the study. Blood samples were collected from these patient's post-acute stroke phase (within 1 month to 1 year after onset). Upon collection, the samples were promptly placed in pre-cooled centrifuge tubes and centrifuged under controlled temperatures to separate clear plasma from cellular precipitates. Subsequently, the samples were stored in an ultra-low temperature freezer at -80 degrees Celsius. The plasma KLK1 levels were quantified using a double antibody sandwich biotin affinity enzyme-linked immunosorbent assay kit. Secondary analyses were conducted using the clinical data, with detailed descriptions of the sample collection and assay protocols outlined in previous publications(Annals of Neurology 2011, 70(2):265-273; Lipids in Health and Disease 2024, 23(1)).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ischemic stroke
We retrospectively gathered information on patients admitted for acute first-ever ischaemic stroke between January 2018 and January 2022. The following individuals were excluded from the study: 1) Those under 18 years of age; and 2) Pregnant women.
The variables gathered included the primary test parameters of patients within 24 hours of admission, encompassing age, gender, smoking and alcohol consumption status, arterial blood pressure, fat-related indicators, comorbidities, and the primary treatments administered within the initial 24 hours.
No intervention
No intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Diagnosis of metabolic syndrome (MetS) according to the criteria established by the Chinese Diabetes Society (CDS) in 2004.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qin Zhang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qin Zhang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TJ-IRB20230830
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.